Cargando…

The role of complement in ATTR amyloidosis: a new therapeutic avenue?

Detalles Bibliográficos
Autores principales:	Panayiotou, Elena, Fella, Eleni, Papacharalambous, Rebecca, Malas, Stavros, Kyriakides, Theodore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642124/ http://dx.doi.org/10.1186/1750-1172-10-S1-P3

Ejemplares similares

Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy
por: Panayiotou, E., et al.
Publicado: (2016)

C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy
por: Panayiotou, Elena, et al.
Publicado: (2017)

Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy
por: Fella, Eleni, et al.
Publicado: (2017)

TUDCA as an autophagic modulator of ATTR V30M Amyloidosis
por: Teixeira, Cristina, et al.
Publicado: (2015)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses
por: Adams, David, et al.
Publicado: (2015)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)
por: Adams, David, et al.
Publicado: (2015)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer’s disease
por: Panayiotou, Elena, et al.
Publicado: (2019)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy
por: Eliahou, Ludivine, et al.
Publicado: (2015)

Comparison of MIBG and Diphosphonate scintigraphy in cardiac involvement of aTTR-FAP
por: Chequer, Renata, et al.
Publicado: (2015)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
por: Fontana , Marianna, et al.
Publicado: (2014)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Imaging cardiac ATTR amyloid
por: Hawkins, Philip N
Publicado: (2015)

Adult spinal cord ependymal layer: a promising pool of quiescent stem cells to treat spinal cord injury
por: Panayiotou, Elena, et al.
Publicado: (2013)

Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis
por: Fritschka, Max, et al.
Publicado: (2017)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness
por: Nativi-Nicolau, Jose N., et al.
Publicado: (2021)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Mass spectrometry analysis of transthyretin (TTR) post-translational modifications (PTMs) in hereditary ATTR: a case-control Spanish experience
por: Vilà-Rico, Marta, et al.
Publicado: (2015)

Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report
por: Dattilo, Philip B
Publicado: (2009)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gpha5a7o3v8v3a27hh4kdmb5ng